India’s Contract Research, Development, and Manufacturing Organization (CRDMO) sector is on a rapid growth trajectory, expected to expand from $3-3.5 billion today to $22-25 billion by 2035. The Boston Consulting Group (BCG) and IPSO report, Unleashing the Tiger: Indian CRDMO Sector 2025, highlights how global pharmaceutical realignments, increasing biologics demand, and India’s cost efficiencies are positioning the country as a leading CRDMO destination.
The report underscores India’s strong foundation in small molecule manufacturing while highlighting new opportunities in biologics, Antibody Drug Conjugates (ADCs), gene therapies, and RNA therapeutics. However, challenges such as talent shortages, regulatory complexities, and supply chain dependencies must be addressed to sustain this growth.
To unlock its full potential, India must scale its workforce 6-7x, streamline regulatory approvals, invest in R&D infrastructure, and enhance domestic production of critical inputs. With the right strategic interventions, India can transition from an outsourcing hub to a global CRDMO leader.
This report provides a comprehensive roadmap for industry stakeholders, investors, and policymakers, outlining actionable steps to drive India’s leadership in pharmaceutical innovation and advanced manufacturing.
The report underscores India’s strong foundation in small molecule manufacturing while highlighting new opportunities in biologics, Antibody Drug Conjugates (ADCs), gene therapies, and RNA therapeutics. However, challenges such as talent shortages, regulatory complexities, and supply chain dependencies must be addressed to sustain this growth.
To unlock its full potential, India must scale its workforce 6-7x, streamline regulatory approvals, invest in R&D infrastructure, and enhance domestic production of critical inputs. With the right strategic interventions, India can transition from an outsourcing hub to a global CRDMO leader.
This report provides a comprehensive roadmap for industry stakeholders, investors, and policymakers, outlining actionable steps to drive India’s leadership in pharmaceutical innovation and advanced manufacturing.